Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035
2.3 Market Size & Forecast, By Segmentation, 2022–2035
2.3.1 Market Size By Drug Type
2.3.2 Market Size By Treatment Type
2.3.3 Market Size By Administration Route
2.3.4 Market Size By Patient Type
2.3.5 Market Size By End User
2.4 Market Share & Bps Analysis By Region, 2025
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Application Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Adoption & Usage Metrics
4.1.1 Percentage (%) of chemotherapy patients receiving prophylactic antiemetic regimens across regions.
4.1.2 Market penetration (%) of 5‑HT3 vs. NK1 vs. dopamine antagonist drug classes.
4.1.3 Average number of antiemetic agents prescribed per chemotherapy cycle.
4.1.4 Hospital adoption rate (%) of guideline‑based combination therapies vs. standalone monotherapy.
4.1.5 Growth (%) in adoption of CINV treatments among geriatric vs. pediatric oncology patients.
4.2 Operational & Performance Metrics
4.2.1 Effectiveness (%) of NK1 antagonist regimens in reducing delayed CINV episodes.
4.2.2 Incidence (%) of breakthrough nausea despite prophylactic treatment.
4.2.3 Patient compliance (%) with oral vs. intravenous antiemetic administration.
4.2.4 Average time (hours) to symptom relief after antiemetic administration.
4.2.5 Regional variations in adherence to NCCN/ASCO CINV treatment guidelines.
4.3 Technology & Innovation Metrics
4.3.1 Development (%) of long‑acting formulations (e.g., palonosetron) vs. short‑acting agents.
4.3.2 Research trends in cannabinoid‑based antiemetics and biosimilars.
4.3.3 Adoption (%) of digital health tools (apps, wearables) for monitoring nausea/vomiting episodes.
4.3.4 Number of clinical trials annually for novel CINV therapies.
4.3.5 Investment (%) in R&D for personalized antiemetic regimens based on genetic markers.
4.4 End‑Use & Market Insights
4.4.1 Regional reduction (%) in chemotherapy discontinuation rates due to effective CINV management.
4.4.2 Shifts in patient preference for oral/transdermal formulations vs. hospital‑based IV therapy.
4.4.3 Influence of reimbursement policies on adoption rates of NK1 antagonists.
4.4.4 Impact of generic drug launches on affordability and accessibility of CINV treatments.
4.4.5 Growth opportunities in emerging markets due to rising cancer incidence and supportive care awareness.
5. CINV Treatment Market Segmental Analysis & Forecast, By Drug Type, 2022 – 2035, Value (USD Billion)
-
- Introduction
5.2 5-HT3 Receptor Antagonist
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2022 – 2035
-
- NK1 Receptor Antagonist
5.4 Dopamine Antagonists
5.5 Corticosteroids
5.6 Others
6. CINV Treatment Market Segmental Analysis & Forecast, By Treatment Type, 2022 – 2035, Value (USD Billion)
6.1 Introduction
6.2 Pharmacological
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2022 – 2035
6.3 Non-pharmacological
6.4 Prophylactic Regimens
6.5 Others
7. CINV Treatment Market Segmental Analysis & Forecast, By Administration Route, 2022 – 2035, Value (USD Billion)
7.1 Introduction
7.2 Oral
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2022 – 2035
7.3 Intravenous
7.4 Subcutaneous
7.5 Others
8. CINV Treatment Market Segmental Analysis & Forecast, By Patient Type, 2022 – 2035, Value (USD Billion)
8.1 Introduction
8.2 Adults
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2022 – 2035
8.3 Geriatrics
8.4 Paediatrics
8.5 Others
9. CINV Treatment Market Segmental Analysis & Forecast, By End User, 2022 – 2035, Value (USD Billion)
9.1 Introduction
9.2 Hospitals
9.2.1 Key Trends
9.2.2 Market Size & Forecast, 2022 – 2035
9.3 Oncology Clinics
9.4 Homecare Settings
9.5 Others
10. CINV Treatment Market Segmental Analysis & Forecast By Region, 2022 – 2035, Value (USD Billion)
10.1 Introduction
10.2 North America
10.2.1 Key Trends
10.2.2 CINV Treatment Market Size & Forecast, By Drug Type, 2022 – 2035
10.2.3 CINV Treatment Market Size & Forecast, By Treatment Type, 2022 – 2035
10.2.4 CINV Treatment Market Size & Forecast, By Administration Route, 2022 – 2035
10.2.5 CINV Treatment Market Size & Forecast, By Patient Type, 2022 – 2035
10.2.6 CINV Treatment Market Size & Forecast, By End User, 2022 – 2035
10.2.7 CINV Treatment Market Size & Forecast, By Country, 2022 – 2035
10.2.7.1 USA
10.2.7.2 Canada
10.3 Europe
10.3.1 Key Trends
10.3.2 CINV Treatment Market Size & Forecast, By Drug Type, 2022 – 2035
10.3.3 CINV Treatment Market Size & Forecast, By Treatment Type, 2022 – 2035
10.3.4 CINV Treatment Market Size & Forecast, By Administration Route, 2022 – 2035
10.3.5 CINV Treatment Market Size & Forecast, By Patient Type, 2022 – 2035
10.3.6 CINV Treatment Market Size & Forecast, By End User, 2022 – 2035
10.3.7 CINV Treatment Market Size & Forecast, By Country, 2022 – 2035
10.3.7.1 Germany
10.3.7.2 UK
10.3.7.3 France
10.3.7.4 Italy
10.3.7.5 Spain
10.3.7.6 Russia
10.3.7.7 Poland
10.3.7.8 Rest of Europe
10.4 Asia-Pacific
10.4.1 Key Trends
10.4.2 CINV Treatment Market Size & Forecast, By Drug Type, 2022 – 2035
10.4.3 CINV Treatment Market Size & Forecast, By Treatment Type, 2022 – 2035
10.4.4 CINV Treatment Market Size & Forecast, By Administration Route, 2022 – 2035
10.4.5 CINV Treatment Market Size & Forecast, By Patient Type, 2022 – 2035
10.4.6 CINV Treatment Market Size & Forecast, By End User, 2022 – 2035
10.4.7 CINV Treatment Market Size & Forecast, By Country, 2022 – 2035
10.4.7.1 China
10.4.7.2 India
10.4.7.3 Japan
10.4.7.4 South Korea
10.4.7.5 Australia
10.4.7.6 ASEAN Countries
10.4.7.7 Rest of Asia-Pacific
10.5 Latin America
10.5.1 Key Trends
10.5.2 CINV Treatment Market Size & Forecast, By Drug Type, 2022 – 2035
10.5.3 CINV Treatment Market Size & Forecast, By Treatment Type, 2022 – 2035
10.5.4 CINV Treatment Market Size & Forecast, By Administration Route, 2022 – 2035
10.5.5 CINV Treatment Market Size & Forecast, By Patient Type, 2022 – 2035
10.5.6 CINV Treatment Market Size & Forecast, By End User, 2022 – 2035
10.5.7 CINV Treatment Market Size & Forecast, By Country, 2022 – 2035
10.5.7.1 Brazil
10.5.7.2 Argentina
10.5.7.3 Mexico
10.5.7.4 Colombia
10.5.7.5 Rest of Latin America
10.6 Middle East & Africa
10.6.1 Key Trends
10.6.2 CINV Treatment Market Size & Forecast, By Drug Type, 2022 – 2035
10.6.3 CINV Treatment Market Size & Forecast, By Treatment Type, 2022 – 2035
10.6.4 CINV Treatment Market Size & Forecast, By Administration Route, 2022 – 2035
10.6.5 CINV Treatment Market Size & Forecast, By Patient Type, 2022 – 2035
10.6.6 CINV Treatment Market Size & Forecast, By End User, 2022 – 2035
10.6.7 CINV Treatment Market Size & Forecast, By Country, 2022 – 2035
10.6.7.1 UAE
10.6.7.2 Saudi Arabia
10.6.7.3 Qatar
10.6.7.4 Egypt
10.6.7.5 South Africa
10.6.7.6 Rest of Middle East & Africa
11. Competitive Landscape
11.1 Key Players' Positioning
11.2 Competitive Developments
11.2.1 Key Strategies Adopted (%), By Key Players, 2025
11.2.2 Year-Wise Strategies & Development, 2022 – 2035
11.2.3 Number of Strategies Adopted By Key Players, 2025
11.3 Market Share Analysis, 2025
11.4 Product/Service & Application Benchmarking
11.4.1 Product/Service Specifications & Features By Key Players
11.4.2 Product/Service Heatmap By Key Players
11.4.3 Application Heatmap By Key Players
11.5 Industry Start-Up & Innovation Landscape
11.6 Key Company Profiles
11.6.1 Merck & Co.
11.6.1.1 Company Overview & Snapshot
11.6.1.2 Product/Service Portfolio
11.6.1.3 Key Company Financials
11.6.1.4 SWOT Analysis
11.6.2 GlaxoSmithKline (GSK)
11.6.3 Novartis
11.6.4 Helsinn Group
11.6.5 Heron Therapeutics
11.6.6 Pfizer
11.6.7 Johnson & Johnson
11.6.8 Roche
11.6.9 Teva Pharmaceutical Industries
11.6.10 Baxter International
11.6.11 Sun Pharma Industries Ltd.
11.6.12 Dr. Reddy’s Laboratories
11.6.13 Cipla
11.6.14 Eisai Co., Ltd.
11.6.15 Accord Healthcare
11.6.16 Mundipharma International
11.6.17 Amgen
11.6.18 Astellas Pharma
11.6.19 Mylan (Viatris)
11.6.20 Lupin Pharmaceuticals
12. Analyst Recommendations
12.1 SNS Insider Opportunity Map
12.2 Industry Low-Hanging Fruit Assessment
12.3 Market Entry & Growth Strategy
12.4 Analyst Viewpoint & Suggestions on Market Growth
13. Assumptions
14. Disclaimer
15. Appendix
15.1 List of Tables
15.2 List of Figures
Frequently Asked Questions
Ans: The key drivers of the Live Fire Training System Market include rising cancer prevalence, increasing chemotherapy use, advancements in antiemetic drugs, and supportive government initiatives drive market growth.
Ans: North America leads with 41.34% of the global market, thanks to advanced oncology infrastructure, high cancer prevalence, and strong adoption of NK1 antagonists.
Ans: The market was valued at USD 6.18 Billion in 2025 and is projected to reach USD 10.85 Billion by 2035 with a CAGR of 5.91% during 2026-2035.
Ans: NK1 Receptor Antagonists (e.g., aprepitant, fosaprepitant) are the fastest‑growing segment, with a CAGR of 6.63%, driven by their effectiveness in delayed CINV and frequent use in combination regimens.
Ans: The 5‑HT3 Receptor Antagonists (e.g., ondansetron, granisetron, palonosetron) dominate with 43.25% market share due to their widespread use in acute CINV management.
Get in touch
